/header_300040.jpg
Home » Media » Press Releases
Debio 8609 Sanvar®
 Date  Article Title
04 Nov 2008 Sanvar® (Debio 8609) for esophageal variceal bleeding - Debiopharm submits response to the FDA
21 Feb 2008 Debiopharm signs Canadian Partner for Sanvar®
23 Oct 2006 Debiopharm signs international license agreements for Sanvar®
05 Sep 2006 Debiopharm and Salix pharmaceuticals sign license agreement for Sanvar®
24 Jul 2006 Debiopharm applies for first europe marketing authorisation for Sanvar® in France
01 Jun 2006 The Debiopharm Group to initiate confirmatory phase III trial for Sanvar® in esophageal variceal bleeding
04 Jan 2005 H3 Pharma receives approvable letter from FDA for Sanvar® for esophageal variceal bleeding
24 Aug 2004 Mexico becomes first country to approve H3 Pharma´s Sanvar® for esophageal variecal bleeding and four other indications
02 Mar 2004 H3 Pharma Inc. Submits new drug application to FDA for Sanvar® IR
03 Dec 2003 H3 Pharma files Mexican registration submission for Sanvar IR in Esophageal Variceal Bleeding
24 Jul 2003 H3 Pharma Inc. announces important step in bringing SANVAR® (vapreotide) to U.S. market
02 Jul 2003 H3 Pharma Inc. Licenses in Sanvar ® (vapreotide) from Debiopharm S.A.
10 Jan 2001 Swiss drug developer Debiopharm S.A. achieves another success in the development of molecules for theraeutic use
 

Latest News

Debiopharm on   Facebook  Linkedin